연구동향 분석

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy

Sanxing Guo Sibylle Loibl Gunter von Minckwitz Silvia Darb-Esfahani Bianca Lederer Carsten Denkert 2020년

논문상세정보
인용/피인용
' PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • PIK3CA H1047R mutation
  • Pathological complete response
  • triple negative breast cancer
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
28 0

0.0%

' PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy' 의 참고문헌

  • mTOR inhibitors in the treatment of breast cancer
    Vinayak S [2013]
  • Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triplenegative primary breast cancers
    Denkert C [2015]
  • Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer
    Denkert C [2010]
  • Tumor PIK3CA genotype and prognosis : a pooled analysis of 4, 241 patients(pts)with early-stage breast cancer(BC)
    Zardavas D [2015]
  • Triple-negative breast cancer
    Foulkes WD [2010]
  • The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells
    Zhao JJ [2005]
  • Targeting the Phosphoinositide 3-kinase Pathway in Cancer
    Liu P [2009]
  • Recommendations from an international expert panel on the use of neoadjuvant(primary)systemic treatment of operable breast cancer : an update
    Kaufmann M [2006]
  • REporting recommendations for tumor MARKer prognostic studies(REMARK)
    McShane LM [2006]
  • Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients
    Ling Deng [2019]
  • Pathological complete response and long-term clinical benefit in breast cancer : the CTNeoBC pooled analysis
    Cortazar P [2014]
  • PIK3CA mutations in breast cancer are associated with poor outcome
    Li SY [2006]
  • PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer : pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
    Loibl S [2016]
  • PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2(her2)therapy in primary HER2-overexpressing breast cancer
    Loibl S [2014]
  • PIK3CA mutation associates with improved outcome in breast cancer
    Kalinsky K [2009]
  • PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials
    Janku F [2013]
  • Neoadjuvant carboplatin in patients with triplenegative and HER2-positive early breast cancer(GeparSixto;GBG 66) : a randomised phase 2 trial
  • Mutational Diversity and therapy response in breast cancer : a sequencing analysis in the neoadjuvant GeparSepto trial
    Loibl S [2019]
  • Mutation of the PIK3CA gene in ovarian and breast cancer
    Campbell IG [2004]
  • High frequency of mutations of the PIK3CA gene in human cancers
    Samuels Y [2004]
  • Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R
    Meyer DS [2013]
  • Descriptive analysis of estrogen receptor(ER)-negative, progesterone receptor(PR)-negative, and HER2-negative invasive breast cancer, the so-called triplenegative phenotype : a population-based study from the California cancer Registry
  • Cancer-specific mutations in PIK3CA are oncogenic in vivo
    Bader AG [2006]
  • Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells
    Isakoff SJ [2005]
  • Biomarker analyses in CLEOPATRA : a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer
    Baselga J [2014]
  • A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
    Berns K [2007]